StockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a report released on Tuesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Price Performance

Shares of NASDAQ TTNP opened at $6.97 on Tuesday. The business’s 50 day moving average is $7.36 and its two-hundred day moving average is $7.16. Titan Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $16.60. The stock has a market capitalization of $6.34 million, a P/E ratio of -0.85 and a beta of 1.33.

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.